|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feng RM, Zong YN, Cao SM and Xu RH:
Current cancer situation in China: Good or bad news from the 2018
Global cancer statistics? Cancer Commun (Lond). 39:222019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pei XQ, He DL, Tian G, Lv W, Jiang YM, Wu
DP, Fan JH and Wu KJ: Prognostic factors of first-line docetaxel
treatment in castration-resistant prostate cancer: Roles of
neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Int Urol Nephrol. 49:629–635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ribeiro R, Monteiro C, Cunha V, Oliveira
MJ, Freitas M, Fraga A, Príncipe P, Lobato C, Lobo F, Morais A, et
al: Human periprostatic adipose tissue promotes prostate cancer
aggressiveness in vitro. J Exp Clin Cancer Res. 31:322012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saloman DS, Bianco C, Ebert AD, Khan NI,
De Santis M, Normanno N, Wechselberger C, Seno M, Williams K,
Sanicola M, et al: The EGF-CFC family: Novel epidermal growth
factorrelated proteins in development and cancer. Endocr Related
Cancer. 7:199–226. 2000. View Article : Google Scholar
|
|
7
|
Ciccodicola A, Dono R, Obici S, Simeone A,
Zollo M and Persico MG: Molecular characterization of a gene of the
‘EGF family’ expressed in undifferentiated human NTERA2
teratocarcinoma cells. EMBO J. 8:1987–1991. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bianco C, Rangel MC, Castro NP, Nagaoka T,
Rollman K, Gonzales M and Salomon DS: Role of Cripto-1 in stem cell
maintenance and malignant progression. Am J Pathol. 177:532–540.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bianco C, Strizzi L, Normanno N, Khan N
and Salomon DS: Cripto-1: An oncofetal gene with many faces. Curr
Top Dev Biol. 67:85–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schier AF and Talbot WS: Nodal signaling
and the zebrafish organizer. Int J Dev Biol. 45:289–297.
2001.PubMed/NCBI
|
|
11
|
Shi S, Ge C, Luo Y, Hou X, Haltiwanger RS
and Stanley P: The threonine that carries fucose, but not fucose,
is required for Cripto to facilitate Nodal signaling. J Biol Chem.
282:20133–20141. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watanabe K, Hamada S, Bianco C, Mancino M,
Nagaoka T, Gonzales M, Bailly V, Strizzi L and Salomon DS:
Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for
‘trans’ activity as a Nodal co-receptor. J Biol Chem.
289:35772–35786. 2007. View Article : Google Scholar
|
|
13
|
Rangel MC, Karasawa H, Castro NP, Nagaoka
T, Salomon DS and Bianco C: Role of Cripto-1 during
epithelial-to-mesenchymal transition in development and cancer. Am
J Pathol. 180:2188–2200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Castro NP, Rangel MC, Nagaoka T,
Salomon DS and Bianco C: Cripto-1: An embryonic gene that promotes
tumorigenesis. Future Oncol. 6:1127–1142. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Strizzi L, Bianco C, Normanno N, Seno M,
Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y,
Sanicola M and Salomon DS: Epithelial mesenchymal transition is a
characteristic of hyperplasias and tumors in mammary gland from
MMTV-Cripto-1 transgenic mice. J Cell Physiol. 201:266–276. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wechselberger C, Ebert AD, Bianco C, Khan
NI, Sun Y, Wallace-Jones B, Montesano R and Salomon DS: Cripto-1
enhances migration and branching morphogenesis of mouse mammary
epithelial cells. Exp Cell Res. 266:95–105. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ,
Du H, Zhang GG, Hu Y, Lu AP, Li JY and Ji JF: Positive association
of up-regulated Cripto-1 and down-regulated E-cadherin with tumour
progression and poor prognosis in gastric cancer. Histopathology.
52:560–568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Strizzi L, Postovit LM, Margaryan NV,
Seftor EA, Abbott DE, Seftor RE, Salomon DS and Hendrix MJ:
Emerging roles of nodal and cripto-1: From embryogenesis to breast
cancer progression. Breast Dis. 29:91–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang C, Chen W, Wang X, Zhao J, Li Q and
Fu Z: Cripto-1 promotes the epithelial-mesenchymal transition in
esophageal squamous cell carcinoma cells. Evid Based Complement
Alternat Med. 2015:4212852015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu CH, Wang Y, Qian LH, Yu LK, Zhang XW
and Wang QB: Serum Cripto-1 is a novel marker for non-small cell
lung cancer diagnosis and prognosis. Clin Respir J. 11:765–771.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wechselberger C, Strizzi L, Kenney N,
Hirota M, Sun Y, Ebert A, Orozco O, Bianco C, Khan NI,
Wallace-Jones B, et al: Human Cripto-1 overexpression in the mouse
mammary gland results in the development of hyperplasia and
adenocarcinoma. Oncogene. 24:4094–4105. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Strizzi L, Bianco C, Normanno N and
Salomon D: Cripto-1: A multifunctional modulator during
embryogenesis and oncogenesis. Oncogene. 24:5731–5741. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prasad CP, Rath G, Mathur S, Bhatnagar D,
Parshad R and Ralhan R: Expression analysis of E-cadherin, Slug and
GSK3beta in invasive ductal carcinoma of breast. BMC Cancer.
9:3252009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koksal IT, Ozcan F, Kadioglu TC, Esen T,
Kilicaslan I and Tunc M: Discrepancy between Gleason scores of
biopsy and radical prostatectomy specimens. Eur Urol. 37:670–674.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schroder FH, Hermanek P, Denis L, Fair WR,
Gospodarowicz MK and Pavone-Macaluso M: The TNM classification of
prostate cancer. Prostate Suppl. 4:129–138. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Steuber T, Erbersdobler A, Graefen M,
Haese A, Huland H and Karakiewicz PI: Comparative assessment of the
1992 and 2002 pathologic T3 substages for the prediction of
biochemical recurrence after radical prostatectomy. Cancer.
106:775–782. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruan H, Li X, Yang H, Song Z, Tong J, Cao
Q, Wang K, Xiao W, Xiao H, Chen X, et al: Enhanced expression of
caveolin-1 possesses diagnostic and prognostic value and promotes
cell migration, invasion and sunitinib resistance in the clear cell
renal cell carcinoma. Exp Cell Res. 358:269–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Coccoadiferro L, Miceli V, Kang KS, Polito
LM, Trosko JE and Carruba G: Profiling cancer stem cells in
androgen-responsive and refractory human prostate tumor celllines.
Ann N Y Acad Sci. 1155:257–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klauzinska M, Castro NP, Rangel MC, Spike
BT, Gray PC, Bertolette D, Cuttitta F and Salomon D: The
multifaceted role of the embryonic gene Cripto-1 in cancer, stem
cells and epithelial-mesenchymal transition. Semin Cancer Biol.
29:51–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ,
Li BW, Cai ZD, Zhu XJ, Liang YX, He HC and Zhong WD: High
expression of ASPM correlates with tumor progression and predicts
poor outcome in patients with prostate cancer. Int Urol Nephrol.
49:817–823. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Conley-LaComb MK, Semaan L, Singareddy R,
Li Y, Heath EI, Kim S, Cher ML and Chinni SR: Pharmacological
targeting of CXCL12/CXCR4 signaling in prostate cancer bone
metastasis. Mol Cancer. 15:682016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo Z, Chen X, Du T, Zhu D, Lai Y, Dong W,
Wu W, Lin C, Liu L and Huang H: Elevated levels of epithelial cell
transforming sequence 2 predicts poor prognosis for prostate
cancer. Med Oncol. 34:132017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu D, Xu B, Chen S, Yang Y, Zhang X, Liu
J, Lu K, Zhang L, Liu C, Zhao Y, et al: Long non-coding RNAs and
prostate cancer. J Nanosci Nanotechnol. 13:3186–3194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo J, Wang M, Wang Z and Liu X:
Overexpression of pleomorphic adenoma gene-like 2 is a novel poor
prognostic marker of prostate cancer. PLoS One. 11:e01586672016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ,
Li BW, Cai ZD, Zhu XJ, Liang YX, He HC and Zhong WD: Overexpression
of ASPM correlates with tumor progression and predicts poor outcome
in patients with prostate cancer. Int Urol Nephrol. 49:817–823.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goltz D, Holmes EE, Gevensleben H, Sailer
V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen
G and Dietrich D: CXCL12 promoter methylation and PD-L1 expression
as prognostic predictors in prostate cancer patients. Oncotarget.
7:53309–53320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang TB, Dong CP, Zhou GC, Lu SM, Luan Y,
Gu X, Liu L and Ding XF: A potential panel of four-long noncoding
RNA signature in prostate cancer predicts BCR-free survival and
disease-free survival. Int Urol Nephrol. 49:825–835. 2017.
View Article : Google Scholar : PubMed/NCBI
|
